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Abstract.
Background: Country differences in resource use and costs of Alzheimer’s disease (AD) may be driven by differences in
health care systems and resource availability.
Objective: To compare country resource utilization drivers of societal costs for AD dementia over 18 months.
Methods: GERAS is an observational study in France (n = 419), Germany (n = 550), and the UK (n = 526). Resource use
of AD patients and caregivers contributing to >1% of total societal costs (year 2010) was assessed for country differences,
adjusting for participant characteristics.
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Results: Mean 18-month societal costs per patient were France D 33,339, Germany D 38,197, and UK D 37,899 (£32,501).
Caregiver time spent on basic and instrumental activities of daily living (ADL) contributed the most to societal costs (54%
France, 64% Germany, 65% UK). Caregivers in France spent less time on ADL than UK caregivers and missed fewer work
days than in other countries. Compared with other countries, patients in France used more community care services overall
and were more likely to use home aid. Patients in Germany were least likely to use temporary accommodation or to be
institutionalized at 18 months. UK caregivers spent the most time on instrumental ADL, UK patients used fewest outpatient
resources, and UK patients/caregivers were most likely to receive financial support.
Conclusion: Caregiver time on ADL contributed the most to societal costs and differed across countries, possibly due to use
of community care services and institutionalization. Other resources had different patterns of use across countries, reflecting
country-specific health and social care systems.
Keywords: Activities of daily living, Alzheimer’s disease, caregivers, costs, health resources
INTRODUCTION
Total societal costs of caring for patients with
Alzheimer’s disease (AD) dementia vary across
countries or regions of Europe with different health
care systems [1, 2]. Available cost studies from
several European countries show a strong positive
relationship between disease severity and total costs
of care [1, 3–8]. Informal care costs form the major
component of societal costs for community-dwelling
AD dementia patients [8–11], and the cost of insti-
tutional care is the other main cost driver in the
long-term care of patients with AD dementia [12].
Differences between countries in total societal
costs of caring for people with AD dementia have
been attributed to differences in study methodology
and/or health care systems [1]. Differences exist in
resource utilization between countries [2], although
there may also be regional variations in the delivery
of care within countries.
Differences in resource use between countries in
the context of their health care system structure and
resource availability are important to understand as
this has a direct influence on costs. However, few
studies have examined resource use in multiple coun-
tries, have a large sample size with a prospective
follow-up, or use standardized measures of resource
use [1]. Resource use has been studied within the mild
and moderate AD dementia population [2] rather than
across the full range of AD dementia stages.
The objective of this study was to compare resource
utilization over 18 months for community-dwelling
AD dementia patients across the three countries in
the GERAS study (France, Germany, and the UK)
[8], focusing on the individual resource use items
with the greatest contribution to country-specific total
societal costs. As total societal costs were unadjusted
for disease severity and would be influenced by the
percentage of patients in each severity group as
well as by country differences in costs of individual
resources, we have focused on the adjusted resource
use item analysis rather than costs.
METHODS
Study design and population
GERAS is an 18-month, multicenter, prospective,
non-interventional cohort study conducted in France,
Germany, and the UK, designed to evaluate the costs
and resource use associated with AD dementia for
community-dwelling patients and their caregivers
[8]. Full details of the study design, patient charac-
teristics, and baseline costs and resource use for each
of the participating countries have been reported [8].
Participants were enrolled between October 2010 and
September 2011.
Inclusion criteria were community-dwelling
patients, aged at least 55 years, presenting within
the normal course of clinical care, diagnosed with
probable AD dementia according to the National
Institute of Neurological and Communicative Dis-
orders and Stroke and the Alzheimer’s Disease and
Related Disorders Association criteria [13], with
a Mini-Mental State Examination (MMSE) score
[14] of ≤26 points, and with an informal caregiver
who was willing to participate in the study and
undertake responsibility for the patient for at least 6
months of the year.
Information was collected for patients and care-
givers at the baseline visit and at 6, 12, and 18 months
during routine care visits. Data collected included
sociodemographics, comorbidities, medications, and
health-related quality of life. Additional patient
assessments included cognitive function (assessed
using the MMSE and the cognitive subscale of
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the Alzheimer’s Disease Assessment Scale [ADAS-
cog] [15]), functional ability (assessed using the
Alzheimer’s Disease Co-operative Study Activities
of Daily Living Inventory [ADCS-ADL] [16]), and
behavioral and psychological symptoms (assessed
using the Neuropsychiatric Inventory [NPI] [17]).
Caregivers also completed the Zarit Burden Interview
(ZBI), which provides a measure of caregiver burden
[18].
Resource use
Resource use by patients and their informal care-
givers was captured using the Resource Utilization
in Dementia (RUD) instrument [19], version RUD
Complete 3.1. This standardized instrument is widely
used for resource use data collection in dementia, has
been validated for use in different care settings (i.e.,
community-living and institutionalized patients) [20,
21], and enables comparison of costs of care across
countries with differing health care provisions [22].
The RUD instrument was administered via an inter-
view with the primary informal caregiver.
Resource use items collected included health care
(e.g., outpatient visits, hospital stays, emergency
room visits), community care services (district nurse,
home aid, food delivery, day care, transportation,
other), changes to patient living accommodation (per-
manent, temporary; institutionalization), caregiver
work status (working for pay, missing work days), and
caregiver time (i.e., time spent caring for the patient
by the primary caregiver). Outpatient visits included
visits to a general practitioner (GP), geriatrician, psy-
chiatrist, neurologist, physiotherapist, occupational
therapist, social worker, psychologist, or other health
care professional.
Caregiver time spent on giving informal care was
recorded as the time spent by the caregiver on
assisting the patient with basic activities of daily
living (ADL; e.g., eating, bathing, dressing, using
the bathroom), instrumental ADL (e.g., housework,
shopping, medication use, financial management),
and supervision (i.e., preventing dangerous events).
The recall period varied for different resource use
items in the RUD and differed for the baseline and
follow-up visits. All baseline resource use was mea-
sured as activity in the previous month. Resource use
at each post-baseline visit is reported for the time
period and units collected in the RUD (e.g., caregiver
time is reported as hours per month, while commu-
nity care visits are reported as the number of visits
over the previous 3 months).
Additional data collected from caregivers dur-
ing the interviews included patient medications,
out-of-pocket expenses, and additional financial sup-
port received (e.g., whether the patient or caregiver
receives money from the government or an insurance
company for assistance or for being a caregiver).
Further information on resource use calculation
over 18 months is provided in the supplemental
material.
Cost estimation
For each country, monthly cost values were esti-
mated by applying country-specific unit costs of
services and products (2010 values) to the health and
social care resource use collected over the 18-month
follow-up period. The unit costs for institutionaliza-
tion are given in Supplementary Table 1. For all
other resource use items, full details of the unit
costs applied and their sources for each country
have already been reported (see the supplementary
material in Wimo et al. [8]) but are also given in Sup-
plementary Table 1. All UK costs in pounds sterling
(£) were converted to Euros (D ) using the conversion
rate £1 = D 1.1661, calculated as the average monthly
exchange rate for 2010, as reported previously [8].
Total societal costs for each country were calcu-
lated using an opportunity cost approach taking into
account productivity loss for working caregivers and
lost leisure time for non-working caregivers. Further
information on cost calculation is provided in the
Supplemental Material.
Statistical analysis
Demographics and baseline characteristics were
summarized using descriptive statistics and were
based on non-missing observations. Comparisons
between countries used Cochran–Mantel–Haenszel
(CMH) tests for categorical data, stratified by MMSE
severity groups, and Analysis of Variance (ANOVA)
with independent factors for MMSE severity and
country for continuous data.
The costs of all individual resource use items at
each follow-up visit (6, 12, and 18 months) and
for the overall 18-month period were summarized
for each country to identify the resource use items
with the greatest contribution to total societal costs
(see Supplementary Table 2). From this analysis,
the following items were included in the analysis of
resource use differences between countries: caregiver
time, community care services, hospital stays, AD
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medications, financial support received, temporary
accommodation, outpatient visits, institutionaliza-
tion, and missing work days. With the exception of
missing work days, these items represented a mini-
mum of 3% of country total societal costs in at least
one country in at least one 6-month visit (see Supple-
mentary Table 2).
For community care services, each type of service
(district nurse, home aid, food delivery, day care,
transportation, other) was analyzed individually as
well as being analyzed as a single combined item.
Unit costs based on the average from all three coun-
tries for each service were applied to each service
to give an overall score, which was then analyzed to
test for differences between countries. Use of aver-
age unit costs is a method for weighting the relative
importance of each service (e.g., a visit from a dis-
trict nurse has greater weighting than a food delivery)
but allows testing for country differences indepen-
dently of differences in costs of services across
countries. Outpatient visits (GP, geriatrician, psy-
chiatrist, neurologist, physiotherapist, occupational
therapist, social worker, psychologist, other) were
treated in the same way, with average unit costs being
assigned against each type of outpatient visit to give
a weighted score.
Differences in resource use between countries
were analyzed using various models (Table 1),
which were selected on the basis of the distribu-
tional assumptions for each resource use item. For
each model, the following factors were included
(in addition to country): patient age, patient sex,
MMSE severity group (mild, moderate, moderately
severe/severe [MS/S]), number of patient comor-
bidities, baseline total ADL score, caregiver age,
caregiver relationship (spouse yes/no), caregiver
working for pay, and baseline score of the outcome
measure (i.e., resource utilization item). In some of
the repeated visits zero-inflated models, certain fac-
tors had to be removed to avoid issues of convergence
of the algorithms for the models.
For the primary analysis, country differences were
assessed through analysis of each resource use out-
come measure by repeated measures models (using
an ‘exchangeable’ correlation structure) of resource
use at each 6-month visit, which uses all available data
and models resource use at each 6-month visit. This
method takes account of the fact that the measures at
different time periods are not independent. Repeated
measures models for zero-inflated negative binomi-
als are not an option through the generalized linear
models (GLMs) in SAS 9.2. A zero-inflated nega-
tive binomial model was run including visit as one
of the factors. This type of model assumed indepen-
dence between each visit. As a sensitivity analysis,
the effect of this assumption was assessed by running
a repeated measures negative binomial model. The
results of this sensitivity analysis are not reported but
were consistent with the main analysis.
Data from the repeated measures models with
gamma distribution and log-link function (caregiver
time, 3-month weighted score for community care
services, and 3-month weighted score for outpa-
tient visits) are presented as least square (LS) means
and 95% confidence limits (CL). Data from the
zero-inflated negative binomial repeated visits mod-
els (community care services, outpatient visits) are
presented as LS mean number of visits for those
with a non-zero response (95% CL). For ease of
interpretation, the odds ratio (OR) of no visits (and
95% CL) have been inverted; therefore, an OR >1
can be interpreted as a greater likelihood of having
a visit compared with the UK (reference country).
Data from the repeated measures logistic regression
models (temporary accommodation, AD medication,
financial support received) are presented as OR (95%
CL). An OR >1 can be interpreted as an increased
likelihood of that outcome compared with the UK.
Data from the GLM repeated measures model with
a negative binomial distribution (caregiver missing
work days, patient hospital stays) are presented as
LS means (95% CL) and OR (95% CL). All p-values
are for country comparisons.
Differences in times to institutionalization were
tested using a proportional hazards model including
country and baseline characteristics as above, and are
reported as hazard ratios (HRs) with 95% CL and
p-value.
Country differences for each resource use item
were also analyzed as a sensitivity analysis by mod-
eling 18-month resource use, which was calculated
as the sum of resource use at each 6-month visit and
was, therefore, limited to patients who had data for
all three follow-up visits (i.e., a completers analysis).
We only describe the results that differed from those
in the primary analysis.
All data were analyzed using SAS software, ver-
sion 9.2 (SAS Institute, Cary, North Carolina, USA).
RESULTS
Overall, 1,495 patients with AD dementia were
analyzed at baseline: 419 patients in France, 550
patients in Germany, and 526 patients in the UK.
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Table 1
Models used to analyze resource use items
Resource utilization item Data Type Distributional assumption Model used
Caregiver time Continuous Gamma GLM – gamma distribution with log link
Community care services
a. District nurse Count Negative binomial
b. Home aid Count Negative binomial
c. Food delivery Count Negative binomial
d. Day care Count Negative binomial GLM – zero-inflated negative binomial model
e. Transportation Count Negative binomial
f. Other Count Negative binomial
Weighted score Continuous Gamma GLM – gamma distribution with log link
Temporary accommodation Binary Binomial Logistic regression model (patient spent nights in
temporary accommodation, yes/no)
Institutionalization Time to Event Proportional hazards Cox proportional hazards model
AD medications Binary Binomial Logistic regression model (patient received AD
medication, yes/no)
Caregiver missing work days Count Negative binomial Analysis restricted to caregivers who work.
GLM – zero-inflated negative binomial model
Hospital stay Count Negative binomial GLM – zero-inflated negative binomial model
Outpatient visits
a. General practitioner Count Negative binomial
b. Geriatrician Count Negative binomial
c. Psychiatrist Count Negative binomial
d. Neurologist Count Negative binomial
e. Physiotherapist Count Negative binomial GLM – zero-inflated negative binomial model
f. Occupational therapist Count Negative binomial
g. Social worker Count Negative binomial
h. Psychologist Count Negative binomial
i. Other Count Negative binomial
Weighted score Continuous Gamma GLM – gamma distribution with log link
Financial support received Binary Binomial Logistic regression model (patient received
financial support, yes/no)
AD, Alzheimer’s disease; GLM, generalized linear model.
The baseline characteristics of the patients and
caregivers participating in the GERAS study are sum-
marized by country in Table 2. Differences across
countries were seen for patient age, sex, time since
AD dementia diagnosis, living alone in their own
home, MMSE score, ADCS-ADL score, and mean
number of comorbidities. Across countries, care-
givers differed for age, sex, and whether they were
the patient’s spouse.
Over 18 months of follow-up, 130 (31%) patients
in France discontinued from the study due to insti-
tutionalization (n = 65; 50%), death (n = 21; 16%), or
other reasons (n = 44; 34%; including lost to follow-
up, physician decision, patient decision). In Germany,
169 (31%) patients discontinued due to institu-
tionalization (n = 55; 33%), death (n = 31; 18%),
or other reasons (n = 83; 49%). In the UK, 185
(35%) patients discontinued due to institutionaliza-
tion (n = 94; 51%), death (n = 40; 22%), or other
reasons (n = 51; 28%).
For patients with completed follow-up visits, miss-
ing data on individual items was minimal (<1%).
Total societal costs
Estimated mean total societal costs per patient
over 18 months by country are summarized in
Fig. 1. For the whole study cohort, mean total
costs were highest in Germany (D 38,197; 95% CL:
36,077–40,375) and lowest in France (D 33,339;
95% CL: 31,172–35,548). When unadjusted coun-
try costs were compared by disease severity, mean
total costs for patients with mild AD dementia at
baseline were highest in the UK (D 30,161; 95% CL:
27,338–33,279), whereas Germany had the highest
mean costs for patients with moderate (D 42,430;
95% CL: 38,613–46,723) and MS/S AD dementia
(D 50,947; 95% CL: 47,506–54,563).
Unadjusted costs of resource use items and
resource utilization by country
The percentage contribution to total societal costs
of individual resource use items at the 6-, 12-, and
18-month visits in each country and for the over-
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Table 2
Summary of patient and caregiver characteristics at baseline by country
Baseline characteristic Country p-value
France Germany UK
Patients
Number of patients 419 550 526
Age, years 79.4 (6.81) 75.2 (7.55) 78.5 (7.79) <0.001
Sex (% female) 62.3 49.6 54.2 <0.001
Years since diagnosis 2.5 (2.41) 2.0 (2.14) 2.2 (2.13) 0.009
Living alone, own home (%) 20.3 16.2 15.0 <0.001
Baseline MMSE score (range 0–30) 17.2 (5.73) 17.7 (6.72) 17.3 (6.40) <0.001
Baseline total ADL score (range 0–78) 47.4 (18.16) 45.5 (21.92) 46.8 (17.69) 0.001
Number of patient comorbidities 1.8 (1.27) 1.4 (1.19) 1.2 (1.15) <0.001
Caregivers
Number of caregivers 418a 549a 526
Age, years 67.9 (12.39) 65.9 (11.78) 68.3 (11.90) 0.001
Sex (% female) 62.4 67.8 61.8 0.004
Caregiver relationship (% spouse) 61.7 67.6 67.5 0.016
Caregiver working for pay (%) 21.5 28.6 20.5 0.457
Data are presented as means (SD) unless otherwise indicated. ADL, Activities of Daily Living; MMSE, Mini-Mental
State Examination. p-values for comparison between countries (Cochran–Mantel–Haenszel tests for categorical
variables and ANOVA with independent factors for MMSE severity and country for continuous variables). aData
missing for one caregiver.
Fig. 1. Estimated mean total societal costs per patient over 18 months by country. UK data were converted to Euros using conversion rate
£1 = D 1.1661. AD, Alzheimer’s disease, MS/S, moderately severe/severe.
all 18-month period in each country (Supplementary
Table 2) showed that caregiver time was the resource
use item that exerted the highest cost contribution in
all three countries, accounting for 54% of the total
costs in France, 64% in Germany, and 65% in the
UK for the overall 18-month period in patients with
resource use data at all three follow-up visits. The rel-
ative contribution of other resource use items to total
costs was much lower and varied between countries.
Notably, community care services resulted in a higher
contribution to total costs in France (15%) than in
Germany (4%) or the UK (7%). Also, additional
financial support accounted for 14% of total costs
in the UK compared with 4% in France and 5% in
Germany (Supplementary Table 2). Over 18 months,
institutionalization rates were 15.5%, 10.0%, and
17.3% in France, Germany, and the UK, respectively,
and in all three countries, the costs of institutionaliza-
tion increased as a percentage of total societal costs
over time at each 6-month visit.
Adjusted country differences in resource use over
18 months
Repeated measures models
Table 3 presents the comparisons between coun-
tries for resource utilization from the repeated
measures analyses. Caregiver time spent on basic
ADL differed across countries (p < 0.001) and was
lower in France (24.4 h/month) than in the UK
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Table 3
Country differences for each resource use item: results from repeated measures models
Resource use item Country p-value
France Germany UK
Caregiver time (h/month)
Basic ADL LS mean (95% CL) 24.4 (20.4–29.2)d 32.8 (28.0–38.4) 36.4 (30.8–43.1) <0.001
Instrumental ADL LS mean (95% CL) 59.5 (53.9–65.7)d 66.5 (61.1–72.4)d 89.3 (82.0–97.3) <0.001
Basic + instrumental ADL LS mean (95% CL) 88.6 (80.1–98.0)d 101.3 (92.8–110.5)d 125.4 (115.9–135.6) <0.001
Community care services (in past 3 months)a
District nurse OR (95% CL) 1.52 (0.94–2.45)e 0.73 (0.45–1.19)f 1.00 <0.001
LS Mean (95% CL) 39.9 (34.3–46.5)d 44.6 (37.6–52.9)d 2.5 (2.1–3.1) <0.001
Home aid OR (95% CL) 4.79 (3.17–7.24)d,e 1.00 (0.64–1.57)f 1.00 <0.001
LS Mean (95% CL) 32.2 (29.1–35.6)d,e 22.3 (19.3–25.8)d,f 43.5 (38.3–49.4) <0.001
Food delivery OR (95% CL) 1.00 (0.47–2.12) 1.28 (0.61–2.69) 1.00 0.759
LS Mean (95% CL) 41.6 (30.7–56.5)d 40.7 (30.9–53.5)d 18.7 (13.1–26.8) <0.001
Day care OR (95% CL) 0.87 (0.55–1.37) 0.76 (0.50–1.16) 1.00 <0.001
LS Mean (95% CL) 16.2 (14.2–18.5)e 21.3 (18.5–24.5)f 17.2 (15.3–19.5) 0.004
Transportation OR (95% CL) 1.39 (0.83–2.30)e 0.54 (0.31–0.95)d,f 1.00 <0.001
LS Mean (95% CL) 10.9 (8.6–13.8)e 22.4 (16.8–30.0)f 16.9 (12.9–22.2) <0.001
Other OR (95% CL) 0.57 (0.29–1.11) 0.58 (0.31–1.06) 1.00 <0.001
LS Mean (95% CL) 13.1 (8.9–19.3) 13.6 (9.2–20.1) 10.6 (7.5–15.1) 0.390
3-month weighted score 507.8 (419.3–614.9)d,e 287.4 (229.3–360.1)f 270.3 (221.9–329.2) <0.001
Temporary accommodation OR (95% CL) 1.29 (0.94–1.78)e 0.40 (0.28–0.59)d,f 1.00 <0.001
(in past 6 months)b
AD medication (in past 6 months)b OR (95% CL) 1.38 (0.75–2.53) 1.23 (0.68–2.22) 1.00 0.573
Caregiver missing work days OR (95% CL) 0.31 (0.04–2.43) 0.19 (0.04–0.85)d 1.00 0.003
(in past 6 months)a LS Mean (95% CL) 2.1 (1.3–3.6)d,e 5.6 (3.9–8.0)f 5.6 (4.0–7.9) <0.001
Hospital stays (in past 6 months)a OR (95% CL) 0.66 (0.39–1.11) 0.81 (0.49–1.32) 1.00 0.187
LS Mean (95% CL) 15.4 (10.9–22.0)d,e 7.2 (5.4–9.5)f 5.9 (4.3–8.1) <0.001
Outpatient visits (in past 3 months)a
General practitionerc LS Mean (95% CL) 2.0 (1.8–2.2)d,e 2.5 (2.2–2.8)d,f 1.5 (1.3–1.7) <0.001
Geriatrician OR (95% CL) 6.42 (0.88–46.71)e 0.12 (0.02–0.63)d,f 1.00 <0.001
LS Mean (95% CL) 0.4 (0.2–0.8)e 3.1 (1.6–6.0)d,f 0.5 (0.2–1.5) <0.001
Psychiatristc LS Mean (95% CL) 0.04 (0.02–0.09)d 0.1 (0.08–0.14) 0.2 (0.1–0.2) <0.001
Neurologist LS Mean (95% CL) 0.5 (0.4–0.8) 0.8 (0.6–1.0) 0.3 (0.1–1.5) 0.092
Physiotherapist OR (95% CL) 2.44 (1.25–4.79)d 2.52 (1.32–4.81)d 1.00 0.003
LS Mean (95% CL) 20.5 (16.9–24.9)d 17.8 (14.9–21.3)d 2.8 (2.1–3.8) <0.001
Occupational therapist OR (95% CL) 0.73 (0.28–1.94)e 1.07 (0.47–2.46)f 1.00 0.009
LS Mean (95% CL) 6.8 (4.3–10.7)d,e 17.1 (13.1–22.3)d,f 1.7 (1.1–2.6) <0.001
Social worker OR (95% CL) 1.50 (0.40–5.56)e 0.03 (0.01–0.13)d,f 1.00 <0.001
LS Mean (95% CL) 0.1 (0.1–0.3)e 31.8 (11.4–88.4)d,f 0.5 (0.3–0.9) <0.001
Psychologist LS Mean (95% CL) 2.8 (0.8–10.0) 3.7 (0.9–15.6) 1.9 (0.2–18.8) 0.822
Other OR (95% CL) 0.24 (0.09–0.65)d 0.21 (0.07–0.59)d 1.00 <0.001
LS Mean (95% CL) 4.3 (3.5–5.2)d,e 1.2 (1.0–1.5)f 1.1 (1.0–1.3) <0.001
3-month weighted score 232.0 (194.9–276.2)d 229.0 (194.1–270.1)d 124.6 (104.9–147.9) <0.001
Financial support received by OR (95% CL) 0.10 (0.07–0.16)d 0.35 (0.25–0.49)d 1.00 <0.001
caregiver/patient
(in past 6 months)b
p-values are for the comparison across countries. AD, Alzheimer’s disease; ADL, activities of daily living; CL, confidence limit; LS, least
squares; OR, odds ratio. aAn OR relates to the likelihood of using this resource use item. An OR >1 can be interpreted as a greater likelihood
of using this resource use item compared with the UK. LS means give the activity for those patients using this resource use item; e.g., number
of visits from a district nurse, number of caregiver missing work days, or number of days spent in hospital in the past 6 months. bAn OR >1
can be interpreted as an increased likelihood of spending time in temporary accommodation, having AD medication or receiving additional
financial support, compared with the UK. cLS means are from the repeated measures negative binomial model. dSignificantly different from
the UK. eSignificantly different from Germany. f Significantly different from France.
(36.4 h/month). Caregiver time spent on instrumen-
tal ADL also differed across countries (p < 0.001) and
was higher in the UK (89.3 h/month) than in France
(59.5 h/month) or Germany (66.5 h/month). Care-
giver time spent on basic + instrumental ADL was
higher in the UK (125.4 h/month) than in France
or Germany (88.6 and 101.3 h/month, respectively;
p < 0.001).
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For community care services, the 3-month
weighted score shows that patients in France used
more community care services than patients in the
other two countries (Table 3). The ORs for the indi-
vidual services show that patients in France were
more likely to receive district nurse visits than
patients in Germany and were more likely to receive
home aid visits than those in the other two coun-
tries. Use of transportation services was less likely
for patients in Germany than for those in the UK
or France. The LS means for the individual com-
munity care service items show that if the service
was used, patients in the UK had fewer district nurse
visits and food delivery, but more home aid services
than patients in the other two countries. Patients in
Germany received more day care and transportation
services than those using these services in France.
The results of the repeated measures model
(Table 3) also show that patients in Germany were
less likely to have spent time in temporary accom-
modation since the last visit than patients in the
UK (OR = 0.40; 95% CL: 0.28–0.59; p < 0.001) or
France (OR versus UK = 1.29; 95% CL: 0.94–1.78).
Use of AD medication (versus no use) did not
differ between countries (p = 0.57). Further anal-
yses showed that memantine only use was more
likely in France (OR = 2.26; 95% CL: 1.07–4.78)
and Germany (OR = 1.88; 95% CL: 0.86–4.12) than
in the UK, although it did not reach statistical sig-
nificance (p = 0.08). Memantine use together with
acetylcholinesterase inhibitors was more likely in
France (OR = 1.57; 95% CL: 0.85–2.91) than in Ger-
many (OR = 0.58; 95% CL: 0.32–1.06; p = 0.01).
Caregivers in Germany were less likely to have
missed work than caregivers from the UK. If they
missed work, French caregivers missed fewer work-
ing days than caregivers in the other two countries
(Table 3).
If French patients were taken into hospital, the
number of days in the past 6 months they stayed in
hospital was greater than for patients in Germany or
the UK (Table 3). No difference in the likelihood of
being hospitalized was observed between the three
countries (p = 0.187).
Patients and caregivers in France and Germany
were less likely to receive financial support than
those in the UK (OR = 0.10 and 0.35 for France
and Germany, respectively; p < 0.001). The 3-month
weighted score for outpatient resources showed that
patients in the UK used fewer outpatient resources
than patients in France or Germany (weighted scores:
125 versus 232 and 229, respectively; p < 0.001). UK
patients had fewer GP visits than those in France and
Germany, while German patients had a higher num-
ber of GP visits than French patients. For patients
who saw a geriatrician or an occupational thera-
pist, those in Germany had more frequent visits to
these health care professionals than patients in the
other two countries. UK patients were less likely
to see a physiotherapist than those in the other two
countries and had fewer visits to a physiotherapist
if seen by one. German patients were less likely
to have been referred to a social worker, but when
they saw one, the number of visits was significantly
greater than for patients in France and the UK. French
patients had fewer visits to a psychiatrist than those in
the UK.
Proportional hazards models with UK as the
reference country showed the likelihood of institu-
tionalization at 18 months was lower for patients in
Germany (HR = 0.59; 95% CL: 0.41–0.84; p = 0.014)
but similar for French patients (HR = 0.84; 95% CL:
0.60–1.18).
Sensitivity analysis: Models of 18-month
resource use
Country comparisons for resource use items from
the 18-month resource use models (completer’s anal-
ysis) gave very similar results. The only difference
from the repeated measures models was that LS mean
caregiver time spent on basic ADL did not differ
between France (425.2 h; 95% CL: 306.9–588.9),
Germany (569.8 h; 95% CL: 428.4–757.9), and the
UK (615.0 h; 95% CL: 456.8–827.9); p = 0.134.
DISCUSSION
Few studies have examined longitudinal resource
use and the cost of caring for patients with AD
dementia or examined the differences in resource
utilization between countries. Our results from the
GERAS study of community-dwelling AD demen-
tia patients and their caregivers showed that informal
caregiver time was the resource item with the great-
est contribution to total societal costs at each level of
AD dementia severity, accounting for 54–65% of the
18-month costs in all three countries (Supplementary
Table 2).
Country differences in societal costs may be due to
differential unit costs being applied and/or to differ-
ences in resource utilization, which are influenced by
the health and social care systems of each country as
well as the availability of and access to care providers.
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Mix of public and private
providers; SHI system, with all
SHI insurers incorporated into
single national exchange [53]
Health care (medical care) and
social care operate as separate
systems with different financing
structures
NHS: provides care including
hospital and physician services
and prescription drugs to all
residents (T40)
SHI system, with 131 competing
SHI insurers (“sickness funds” in
a national exchange); high
income can opt out for private
coverage [57]
The organizational structure and
governance of the health care
system is different in each of the
four countries of the UK
(England, Scotland, Wales, and
Northern Ireland), and they have





income and payroll tax; general
tax revenue, earmarked taxes
Employer/employee earmarked
payroll tax; general tax revenue






Coverage is universal: Coverage is universal for all legal
residents [57]:
Coverage is universal and is mostly
free at point of use [42]SHI
SHI – 86% of population Outpatient prescription drugs are
subject to a co-payment in
England [42]. Prescriptions are








Patients pay up-front for services,
and a proportion is reimbursed
by government Some co-payments are required






Approx. 90% of people buy or
receive government vouchers for
cost-sharing; some non-covered
benefits [53]
Approx. 11% of people opt-out of
SHI system for private coverage
only [57]. Some complementary




Approx. 11% of people buy private
insurance for private facilities,
mainly for elective surgery and
consultations with specialists
[42]
Caps on cost sharing None [53] Yes [57] No general cap for out-of-pocket
expensesD 50 cap on deductibles for
consultations and services
2% of income; 1% of income for
chronically ill and low-income
people
Prepayment certificate with £29
per 3 months or £104 per year
ceiling for those needing a large






individuals, chronically ill and
disabled, and children [53]
Children and adolescents aged <18
years exempt [57]
Drug cost-sharing exemption for
low-income individuals, older
people, children, pregnant
women and new mothers, and
some disabled/chronically ill
individuals. Financial assistance
with transport costs available to






Free to choose any doctor/hospital Easy access to specialists but
gatekeeping system is now
encouraged
Mainly through GPs who act as
gatekeepers for secondary care
[42]
Can go direct to specialist (but
referral for most specialist
consultations has to be issued by
a primary care physician or could
lead to incomplete SHI coverage
for the patient) [53]
Patients can choose which hospital
to visit, and the government has
introduced the right to choose
a particular specialist within
a hospital (albeit not yet fully
implemented) [42]
(Continued)




Mental health (including long-term medical and social care)
Mental health care Services provided by health care
sector take the form of both
public and private care in both
outpatient and inpatient settings.
Emphasis is on community-
based provision [53]
Ambulatory psychiatrists have been
made coordinators of a new set
of SHI-financed benefits called
“sociotherapeutic care” (which
requires referral by a GP), to
encourage the chronically
mentally ill to use necessary care
and to avoid unnecessary
hospitalizations [57]
Integral part of NHS; serious
illness treated through mental
health or hospital trusts. Part of
this is supported through
community-based staff.
A quarter of mental health care
hospital-based services are






Long-term care for elderly and
disabled belongs to the “health
and social care sector”. Care may
be provided at home or in
residences [53]
Long-term care covered by
a separate insurance scheme
(LTCI) [57]
Long-term care is provided by the
health and social care sector and
includes both residential care and
home care [42]
Home care is provided mainly by
self-employed physicians and
nurses, with some community
nursing services (SSIAD). These
services are needs based
This is mandatory and usually
provided by the same insurer as
health insurance (has a similar
public–private mix)
State-funded social care is not
universal
Residential care is provided in
retirement homes and long-term
care units
Anybody with a physical or mental
illness or disability (who has
contributed for at least 2 years)
can apply for benefits under this
scheme
NHS pays for some long-term care
SHI covers medical care costs, but
families incur the costs for
housing. Temporary care is
covered without restrictions
Both home care and institutional
care are delivered by private
providers
Residential and home care is
needs-tested and means-tested
Long-term care beds in institutions
and hospitals: 59.0 per 1,000
population aged ≥65 years [49]
Long-term care beds in institutions
and hospitals: 53.1 per 1,000
population aged ≥65 years [49]
Most long-term care is provided by
local authorities and private
sector; funded by mix of
public–private payments
Long-term care beds in institutions
and hospitals: 49.5 per 1,000
population aged ≥65 years [49]
Financial support APA – means-tested allowance for
community-dwelling patients
aged >60 and needing assistance
with ADL
LTCI benefits are dependent on
evaluation of individual need.
Persons evaluated as in need of
care are assigned to one of three
levels of care (I, II, or III)
depending on the extent of the
need for care [57]. Persons who
need general care and domestic
help as a result of dementia but
who have not reached Care Level
I are allocated to Care Level 0
and are entitled to a range of
benefits, which are broader since
1 Jan 2015 after the First Act to
Strengthen Long-Term Care was
passed [65]
Patient Attendance Allowance
The allocated amount is related to
the person’s own resources and
level of dependency
Beneficiaries can choose in-kind




FAP supporting caregivers and
ensuring patients’ quality of life
in addition to enforcing
compliance with guidelines and
promoting evidence-based
practice [28]
No national dementia plan but
Alliance for People with
Dementia: The Fields of Action
[32, 33]
England, Scotland, Ireland, and
Wales have separate national
dementia strategies [34–37]
S3 Guidelines for the diagnosis and
treatment of Alzheimer’s disease
[30, 31]
NICE guidelines and quality
standards for dementia care are
available [38, 39, 40]
(Continued)








Health and social care services,
including community-based




are less frequently used than
those in France
Community-based services overall
are less frequently used
compared with France
The FAP facilitates caregiver
support, including respite care,
consolidates caregiver rights and
training, and improves caregiver
health monitoring
National dementia strategies
improve the care, support, and
advice offered to people with






Medical care for people with
dementia is reimbursed at 100%
Care for dementia available
through LTCI
A wide range of health and social
services are provided by the NHS
specifically for patients with
dementia and their caregivers
Many services and nursing homes
do not respond specifically to the
needs of patients with dementia
A small, growing number of
provisions for people with
dementia and caregivers for






Home care and support plan is
available and coordinated by the
GP in conjunction with
a specialist (as applicable)
Social and healthcare professionals
are involved in the provision of
care and support to people with
dementia in residential care or at
home
Social and healthcare professionals
are involved in the provision of
care and support to people with





(ANESM) that cover life habits,
washing, nutrition, mobility,







Support for informal caregivers is
implemented via the FAP. Issues
addressed include respite,
training, counseling and support,
and case management
Support for informal caregivers in
the context of LTCI is addressed
in national policies specific to
respite (§39 SGB XI, §41 SGB
XI, §42 SGB XI), training (§45
SGB XI), counseling and support
(§7 SGB XI), and case
management (§§7, 92 SGB XI)
Support for informal caregivers is
addressed in national policies of
England, Wales, and Northern
Ireland [34, 36, 37], and in 2010,
the Scottish Government
published Caring Together: The
Carers Strategy for Scotland
2010–15 [66]
Since 2015, the First Act to
Strengthen Long-term Care has
expanded the benefits to support
caregiving relatives [65]
aMuch of the general information is adapted from Table 1 in International Profiles of Health Care Systems, 2014 [67]. bMost of the
dementia-specific information is taken from [68]. ADL, activities of daily living; ANESM, Agence Nationale de l’Evaluation et de la qualité
des établissements et Services Sociaux et Médico-Sociaux; APA, Allocation Personnaliseé d’Autonomie; DGPPN, German Society for
Psychiatry, Psychotherapy and Neurology; FAP, French Alzheimer Plan; GP, general practitioner; LTCI, long-term care insurance; NHS,
National Health Service; NICE, National Institute for Health and Care Excellence; PHI, private health insurance; SGB XI, German care
insurance law (Sozialgesetzbuch XI); SHI, statutory health insurance; SSIAD, Services de Soins Infirmiers á Domicile; VHI, voluntary
health insurance.
Our analyses used country-specific unit costs and
examined differences in resource use between coun-
tries after controlling for key patient and caregiver
characteristics. We will interpret and explain our find-
ings in the context of each country’s health and social
care systems, or strategies for dementia care that were
in place at the time the GERAS study was performed
(years 2010–2013) (Table 4).
Informal caregiver time
As caregiver time was the predominant resource
use item driving total societal costs in all three coun-
808 C. Reed et al. / Country Differences in Resource use for AD
tries, we have tried to identify any country differences
in the composition of informal care. The unit costs
applied for informal caregiver time were lower in the
UK than in the other two countries (see Supplemen-
tary Table 1). Thus, the higher percentage of total
costs in the UK is likely to be due to more time spent
caring.
Indeed, caregivers in the UK spent more time
on instrumental ADL than caregivers in France and
Germany (Table 3), independent of the sex of the
caregiver, and indicates a lack of formalized support
to assist with daily activities. Informal caregivers in
the UK therefore appear to shoulder much of the bur-
den of caring for AD dementia patients, with less
use of community care services and outpatient visits,
despite health and social care being largely free at the
point of use. This is consistent with a recent report
on dementia care in the UK, which stated that infor-
mal caregiver time ranged from an estimated 13 hours
per week for patients with mild dementia to 46 hours
per week for severe dementia and that only 12% of
the 570,000 people living with dementia in England
received relevant social care services [23]. Further-
more, a national survey of caregivers of people with
dementia in the UK found that a large number are not
receiving the support they need from health and care
services [24].
French caregivers spent less time on basic ADL
than caregivers in the UK. As French patients use
more community care services overall, they may be
receiving assistance for self-care tasks from exter-
nal sources, such as district nurses or home helps
(as indicated by the greater frequency of district
nurse visits and increased likelihood of home aid vis-
its, similar to findings from the ICTUS study [2]).
Community-dwelling patients aged over 60 years
and needing assistance with ADL in France can
receive a means-tested allowance (Allocation Per-
sonnalisée d’Autonomie [APA]) to encourage use
of professional services [25]. This assistance may
also explain why French caregivers missed fewer
work days. Although UK patients can receive an
Attendance Allowance and caregivers may be eligi-
ble for a Carer’s Allowance, there is evidence that
up to two-thirds of informal caregivers in the UK are
not having their needs assessed or needs met once
assessed [23]. However, our results show that UK
caregivers/patients are more likely to receive financial
support than those in the other two countries.
National dementia strategies in each country
(France: Neurodegenerative disease plan [26–28];
Germany: Alliance for People with Dementia [29,
30]; UK: country specific national dementia strate-
gies [31–34]) all aim to support informal caregivers
and/or facilitate professional services to maintain
community living.
Community care services
The UK had the lowest use of community care ser-
vices. When looking into individual services, patients
in the UK were less likely to receive home aid ser-
vices than French patients, although UK patients had
more time spent on home aid when received. UK
patients also used less food delivery and had fewer
district nurse visits compared with France and Ger-
many. Knapp et al. [35] remarked on the difficulty of
comparing community care services between coun-
tries as the services have different definitions and are
not equivalent. In 2011, of the people receiving social
care services for dementia in England, 58% received
community-based services, while 28% were in res-
idential care and 14% in nursing care [23]. Most
local authorities charge a means-tested contribution
from patients for home care and residential care [36].
Nursing home care is paid for by the National Health
Service (NHS) only if the patient has been assessed
as fulfilling continuing NHS health care criteria [37];
however, as there is no medical treatment in more
advanced AD dementia, the majority of these patients
are in social care or self-funded.
In our analysis, the use of day care in the UK was
surprisingly low, but this may reflect the 49% fall in
the number of older people using day care centers
between 2005/6 and 2012/13 reported by Age UK in
their Care in Crisis 2014 briefing document [38] as
a result of cuts in funding.
The use of community care services overall was
slightly higher in Germany than in the UK but signif-
icantly less than in France. German patients were less
likely to use transportation services than patients in
the other countries, but had a higher use than French
patients in those that received these services. German
patients were less likely to spend time in temporary
accommodation and were less likely to be institu-
tionalized during the 18-month follow-up period of
the study than patients in the other two countries.
Our results are consistent with previous comparisons
of the percentage of the older population living in
care homes in these countries [35]. The lower rate
of institutionalization among German patients means
keeping them living at home for longer, which is an
aim of German health care policy and the long-term
care insurance system. This and the lack of specific
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geriatric health care services in Germany is likely to
impact on utilization of social care/support services
as well as costs.
The greater use of community care services in
France may indicate that health and social care ser-
vices are better developed in France and may reflect
the benefits offered by the French Alzheimer Plan
[26, 28]. However, patients and caregivers in France
were less likely to receive additional financial support
than those in the UK. In France, the APA allowance
for dependent elderly persons typically covers the
general expenses for day care and home help ser-
vices. In their study of the costs of AD dementia
in France, Gerves et al. [25] found that only 29%
of community-dwelling patients with AD dementia
received an APA and concluded that the APA cov-
ered only about one-fifth of the total costs of care for
AD dementia patients.
Financial support is not usually included in esti-
mations of total societal costs because it represents
transfer costs. Financial support is associated with
resource use and informal caregiver time but we only
included financial support in our cost calculation if
it was higher than the combined costs of community
care services, consumables, and structural changes.
In a cross-sectional sample of French elderly patients
living with mild to moderate AD dementia (PLASA
study), patient financial support was associated with
greater use of formal care (especially home help)
and less use of informal care [39]. Additionally, our
sample of French patients was also more likely to
have stays in temporary accommodation than Ger-
man patients, possibly due to the provision of respite
care under measure one of the French Alzheimer Plan
[28].
Health care resource use
Patients in the UK had fewer GP visits, and a lower
percentage of patients in the UK consulted neurolo-
gists or physiotherapists, during the 18-month period
than patients in the other two countries (data avail-
able upon request). Neurologists in the UK rarely
see AD dementia patients, but may see those with
early-onset dementia. More patients in the UK con-
sulted a psychiatrist compared with those in France
(data available upon request), and, when seen, had
more visits to a psychiatrist than French patients.
These observations may depend on the specialist that
patients are seeing in the memory clinic. The spe-
cialty of the investigators participating in the GERAS
study varied between countries [8]; in the UK,
79% were psychiatrists and 16% were geriatricians,
whereas in France, 64% were geriatricians, and in
Germany, 49% were neurologists and 41% were psy-
chiatrists. Patients in the UK used fewer outpatient
resources overall than patients in the other two coun-
tries, and spent fewer days in hospital than French
patients, who also spent more days in hospital than
patients in Germany.
In the UK, health care is mainly provided by the
NHS, which is largely free at the point of use, includ-
ing primary care, inpatient and outpatient hospital
care, and some long-term health care (e.g., for those
with continuing medical or skilled nursing needs)
[36]. Also, medication is free to people aged over 60
years. The first point of contact for most patients is
the GP, who plays a gatekeeping role in determining
access to specialist services.
Our findings are consistent with the high use of
outpatient services (88%) reported previously for
home-living German AD dementia patients [40].
They are probably the result of the broad range of
health care services offered in Germany and the easy
access to specialists.
In France, health care is largely financed by
government national health insurance [41]. Patients
usually pay up-front for the service provided and then
a proportion of the payment is reimbursed immedi-
ately by the government [42] with 100% of medical
care costs refunded back to patients in cases of costly
or long-term ailments [41].
No difference in whether AD medication was taken
(or not) was observed between countries, although
the UK had the lowest use. Further analyses by med-
ication type have shown a few differences between
countries (e.g., less use of memantine in the UK,
which is in line with country-specific treatment
guidelines [43, 44] and a systematic review in Ger-
many [45]). However, AD medication use accounts
for only a small proportion of total costs in each
country (8–14%; Supplementary Table 2).
Caregiver support
An emerging point from this study is that caregiver
support may be important in determining informal
caregiver time and, ultimately, cost. As caregiver
time is such a large component of the societal costs
associated with AD dementia, better support and
interventions for caregivers of community-dwelling
patients have the potential to reduce societal costs.
The French Alzheimer Plan [28] highlights several
strategies for caregiver support, including respite
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care, consolidating caregiver rights and training, and
improving caregiver health monitoring. This type of
support may have contributed to French caregivers
missing the fewest work days in our study. Germany
does not currently have a national dementia plan, but
one of the four fields of action in the Alliance for Peo-
ple with Dementia is to provide support for people
with dementia and their families [30]. In the UK, the
national dementia strategies for England [31], Scot-
land [32], Wales [34], and Northern Ireland [33] all
aim to improve the care, support, and advice offered
to people with dementia and their caregivers.
Study strengths
Our study has several strengths. We recruited
a large sample of community-dwelling patients with
AD dementia and used longitudinal data collected
over 18 months. We used a standardized instru-
ment (RUD) for collecting resource use data across
the three participating countries, which allowed us
to compare resource utilization between countries.
To enable us to reflect total societal costs, gaps
in resource use were met by asking specific ques-
tions on out-of-pocket expenses, such as structural
changes required or consumables purchased by fam-
ilies. Additional payments to the patient or caregiver
for the task of caregiving were also collected, but
cost estimates were specified to avoid double count-
ing. We adjusted our models for several patient and
caregiver characteristics, and analyzed country dif-
ferences in resource use by two methods: first, we
used repeated measures analysis of all available data
at each 6-month visit; and second, we pooled the
data from patients with data at all three follow-up
visits (completers). The results from these models
generally gave similar findings. Years of education
for the patient were not included in the current models
because we did not find this variable to be associ-
ated with resource use in a previous publication [46].
Country differences in resource use still existed after
additional analyses adjusted for patient years of edu-
cation (data available upon request).
Study limitations
This study has several limitations. First, the
GERAS study population was a clinic-based sample,
and all patients were living in the community. Infor-
mation was available over 18 months of follow-up
or until patients left the study, some due to institu-
tionalization or death. Thus, our analyses of resource
use are only for community-dwelling patients and
cannot be extended to patients living permanently
in residential care, as resource utilization patterns
differ between community-dwelling and institution-
alized dementia patients [47]. Also, the sample was
enrolled as approximately equal numbers of patients
with mild, moderate, and MS/S AD dementia, so does
not reflect the general prevalence by disease sever-
ity and, therefore, is not fully representative of all
patients with AD dementia. However, our resource
use analyses were adjusted for AD dementia sever-
ity. Second, as resource use was collected at each visit
via an interview with the caregiver, it may be subject
to recall bias. However, with prospective follow-up
and the use of diary records, this bias has been min-
imized as much as possible. Also, we only analyzed
time spent providing informal care by the primary
caregiver, which could lead to an underestimation of
informal caregiving time as it is possible that many
patients receive care from several family members.
Conclusions
This study showed that differences in contribu-
tions of the components of societal cost between
France, Germany, and the UK in the care of AD
dementia patients reflected differences in the utiliza-
tion of available resources across these countries.
All patients were community dwelling at baseline,
with rates of institutionalization over the 18-month
follow-up period dependent on baseline AD demen-
tia severity. Informal caregiver time was the main
contributor to societal costs. Caregiver time on basic
and instrumental ADL differed across countries,
some of which may be explained by use of com-
munity care services. Other differences in resource
use across countries reflected the health and social
care systems but had limited influence on societal cost
differences.
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